Jefferies Financial Group Forecasts Strong Price Appreciation for Envista (NYSE:NVST) Stock

Envista (NYSE:NVST) had its price objective hoisted by Jefferies Financial Group from $20.00 to $22.00 in a research report report published on Thursday morning,Benzinga reports. They currently have a hold rating on the stock.

Several other equities analysts have also recently commented on NVST. Needham & Company LLC restated a “hold” rating on shares of Envista in a research report on Thursday, October 31st. Robert W. Baird lifted their price target on Envista from $17.00 to $22.00 and gave the company a “neutral” rating in a research report on Thursday, October 31st. Stifel Nicolaus upped their price objective on shares of Envista from $18.00 to $21.00 and gave the stock a “buy” rating in a research report on Wednesday, October 23rd. Leerink Partnrs raised shares of Envista from a “strong sell” rating to a “hold” rating in a research note on Thursday, October 31st. Finally, Piper Sandler boosted their price target on shares of Envista from $16.00 to $17.00 and gave the stock a “neutral” rating in a research note on Thursday, October 31st. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Envista currently has an average rating of “Hold” and a consensus target price of $20.13.

Envista Stock Up 1.1 %

Shares of Envista stock opened at $21.28 on Thursday. The company’s 50-day moving average price is $19.99 and its 200-day moving average price is $18.78. Envista has a 12-month low of $15.15 and a 12-month high of $24.79. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.08 and a quick ratio of 1.77.

Envista (NYSE:NVST) last posted its earnings results on Wednesday, October 30th. The company reported $0.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.03. The business had revenue of $601.00 million for the quarter, compared to analysts’ expectations of $590.34 million. Envista had a negative net margin of 53.42% and a positive return on equity of 3.76%. The business’s revenue for the quarter was down 4.8% compared to the same quarter last year. During the same period in the prior year, the company posted $0.43 EPS. As a group, research analysts expect that Envista will post 0.72 earnings per share for the current year.

Institutional Trading of Envista

Several hedge funds have recently added to or reduced their stakes in the business. Hantz Financial Services Inc. increased its holdings in shares of Envista by 146.6% in the fourth quarter. Hantz Financial Services Inc. now owns 110,489 shares of the company’s stock worth $2,131,000 after buying an additional 65,679 shares during the period. KBC Group NV grew its position in Envista by 63.9% during the 4th quarter. KBC Group NV now owns 7,903 shares of the company’s stock worth $152,000 after acquiring an additional 3,082 shares during the last quarter. Hedges Asset Management LLC increased its stake in Envista by 13.9% in the 4th quarter. Hedges Asset Management LLC now owns 53,300 shares of the company’s stock worth $1,028,000 after purchasing an additional 6,500 shares during the period. Profit Investment Management LLC lifted its position in Envista by 6.0% in the fourth quarter. Profit Investment Management LLC now owns 127,597 shares of the company’s stock valued at $2,461,000 after purchasing an additional 7,226 shares during the last quarter. Finally, Thurston Springer Miller Herd & Titak Inc. purchased a new stake in shares of Envista during the fourth quarter valued at approximately $53,000.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.